View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 6, 2017

Asceneuron to initiate Phase I trial of ASN120290 in healthy subjects

Swiss-based pharmaceutical firm Asceneuron is planning to initiate a Phase I clinical trial of ASN120290 in healthy volunteers, following the regulatory approval.

Swiss-based pharmaceutical firm Asceneuron is planning to initiate a Phase I clinical trial of ASN120290 in healthy volunteers, following the regulatory approval.

Part of the class of O-GlcNAcase enzyme inhibitors, ASN120290 is an oral tau inhibitor that targets toxic neurofibrillary tau tangle accumulation to counter neurodegenerative diseases such as dementia.

Neurofibrillary tangles are reported to be the primary cause for neurodegeneration and clinical symptoms.

The randomised, double-blind, placebo-controlled Phase I trial is designed to evaluate the safety, tolerability, food effect, pharmacokinetics and pharmacodynamics of single and multiple doses of the product.

Asceneuron chief executive officer and co-founder Dirk Beher said: “This is a significant milestone for Asceneuron and marks our transition to a clinical stage company.

"It is also a major achievement for our scientific team as ASN120290 is our first in-house developed molecule reaching the clinic and was designed to easily enter the brain.

"This is a significant milestone for Asceneuron and marks our transition to a clinical stage company."

"New approaches to treat dementia are urgently required and preventing toxic tau tangle formation with our O-GlcNAcase inhibitor represents a new mechanism of action.”

The optimal dose selection of ASN120290 for future studies will be supported by the assessment of a blood-based biomarker in the trial.

Next year, the firm plans to further investigate ASN120290 in a Phase II proof-of-concept trial for the treatment of the orphan tauopathy disease progressive supranuclear palsy (PSP), after the successful completion of Phase I study.

Preclinical studies indicated that ASN120290 can minimise the accumulation of the tau protein toxic aggregates into neurofibrillary tangles.


Image: CT illustrating progressive supranuclear palsy. Photo: courtesy of Dr Laughlin Dawes/Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena